Kevin Sharp, Executive Vice President and Head of Sales and Operations, Samsung Biologics, a CDMO of biologics and advanced therapies, outlined the company’s multi-faceted investment plan at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week. The company’s investment approach rests on three key drivers: geographic diversification to bolster supply-chain resilience, scalable manufacturing to meet rising market demand, and pipeline flexibility to accommodate an increasingly diverse set of programs.  

With this framework, Samsung Biologics announced the acquisition of its first US biomanufacturing site in Rockville, Maryland. The $280-million investment adds 60,000 L of capacity, consisting of two cGMP manufacturing plants supporting both clinical and commercial production, and over 500 skilled employees’ acquisition. The acquisition, which  closed in late March 2026, brings the company’s total manufacturing capacity to 845,000 L 

Looking ahead, Samsung Biologics says it plans to make additional investments at the site, including a capacity expansion, potentially bringing the site’s total capacity to up to 100,000 L, along with infrastructure enhancements and upgraded technologies from its Songdo Bio Campuses in South Korea.   

In addition to the Rockville acquisition, Samsung Biologics reported that it has secured 46.31 acres of land in Songdo, South Korea, for Bio Campus III, leveraging its proximity to the company’s existing two Bio Campuses there and supply-chain ecosystem in the area. This campus will house development and manufacturing facilities designed for next-generation modalities, including cell and gene therapies, bioconjugates, and antibody-based vaccines. By 2034, the campus is expected to house four or more multimodality plants, supported by a total investment of $4.8 billion to advance innovative biologics. 

The company also announced a $34-million partnership with Eli Lilly and Company to create Lilly Gateway Labs, an open-innovation center within Samsung Biologics’ Bio Campus II, with the lab scheduled to open in July 2027. The five-story facility will function as a shared innovation hub supporting up to 30 emerging biotechnology companies jointly selected by Samsung Biologics and Lilly. Resident companies will gain access to strategic capital, lab space and technology, and research and development capabilities to help scale projects from concept to commercial production. 

Lastly, Samsung Biologics reported that it has joined the Coalition for Epidemic Preparedness Innovations’ (CEPI) Vaccine Manufacturing Facility Network (VMFN), receiving $20 million in funding to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. This partnership aims to accelerate availability of protein-based vaccines, with guaranteed access to up to 50 million doses to expand the company’s role in supporting a reliable and agile vaccine supply ecosystem.